关注
Carmine De Angelis, MD, PhD
Carmine De Angelis, MD, PhD
University of Naples "Federico II", Naples (Italy) - Baylor College of Medicine, Houston (Texas)
在 bcm.edu 的电子邮件经过验证
标题
引用次数
引用次数
年份
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
R Jeselsohn, G Buchwalter, C De Angelis, M Brown, R Schiff
Nature reviews Clinical oncology 12 (10), 573-583, 2015
6152015
Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
G Bianchini, C De Angelis, L Licata, L Gianni
Nature reviews Clinical oncology 19 (2), 91-113, 2022
6102022
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up
L Malorni, PB Shetty, C De Angelis, S Hilsenbeck, MF Rimawi, R Elledge, ...
Breast cancer research and treatment 136, 795-804, 2012
2452012
Towards personalized treatment for early stage HER2-positive breast cancer
K Goutsouliak, J Veeraraghavan, V Sethunath, C De Angelis, CK Osborne, ...
Nature Reviews Clinical Oncology 17 (4), 233-250, 2020
2412020
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
X Fu, R Jeselsohn, R Pereira, EF Hollingsworth, CJ Creighton, F Li, ...
Proceedings of the National Academy of Sciences 113 (43), E6600-E6609, 2016
1562016
The changing role of ER in endocrine resistance
A Nardone, C De Angelis, MV Trivedi, CK Osborne, R Schiff
The Breast 24, S60-S66, 2015
1412015
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
A Prat, T Pascual, C De Angelis, C Gutierrez, A Llombart-Cussac, T Wang, ...
JNCI: Journal of the National Cancer Institute 112 (1), 46-54, 2020
1252020
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer
X Fu, R Pereira, C De Angelis, J Veeraraghavan, S Nanda, L Qin, ...
Proceedings of the National Academy of Sciences 116 (52), 26823-26834, 2019
1252019
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy
M Giuliano, H Hu, YC Wang, X Fu, A Nardone, S Herrera, S Mao, ...
Clinical Cancer Research 21 (17), 3995-4003, 2015
1222015
The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer
R Jeselsohn, C De Angelis, M Brown, R Schiff
Current oncology reports 19, 1-8, 2017
1132017
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
R Jeselsohn, MI Cornwell, M Pun, G Buchwalter, M Nguyen, C Bango, ...
Proceedings of the National Academy of Sciences 114 (22), E4482-E4491, 2017
1122017
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
X Xu, C De Angelis, KA Burke, A Nardone, H Hu, L Qin, J Veeraraghavan, ...
Clinical Cancer Research 23 (17), 5123-5134, 2017
1112017
Tamoxifen resistance in breast cancer is regulated by the EZH2–ERα–GREB1 transcriptional axis
Y Wu, Z Zhang, ME Cenciarini, CJ Proietti, M Amasino, T Hong, M Yang, ...
Cancer research 78 (3), 671-684, 2018
952018
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance
M Bi, Z Zhang, YZ Jiang, P Xue, H Wang, Z Lai, X Fu, C De Angelis, ...
Nature cell biology 22 (6), 701-715, 2020
912020
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer
C Guarducci, M Bonechi, M Benelli, C Biagioni, G Boccalini, D Romagnoli, ...
NPJ breast cancer 4 (1), 38, 2018
912018
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing …
MF Rimawi, C De Angelis, A Contreras, F Pareja, FC Geyer, KA Burke, ...
Breast cancer research and treatment 167, 731-740, 2018
892018
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
S De Placido, C Gallo, M De Laurentiis, G Bisagni, G Arpino, MG Sarobba, ...
The Lancet Oncology 19 (4), 474-485, 2018
882018
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer
G Arpino, C De Angelis, M Giuliano, A Giordano, C Falato, ...
Oncology 77 (Suppl. 1), 23-37, 2010
842010
Immune response against head and neck cancer: biological mechanisms and implication on therapy
F Perri, F Ionna, F Longo, GDV Scarpati, C De Angelis, A Ottaiano, G Botti, ...
Translational oncology 13 (2), 262-274, 2020
692020
De-escalation of treatment in HER2-positive breast cancer: determinants of response and mechanisms of resistance
J Veeraraghavan, C De Angelis, JS Reis-Filho, T Pascual, A Prat, ...
The Breast 34, S19-S26, 2017
662017
系统目前无法执行此操作,请稍后再试。
文章 1–20